2680eP Metastatic fumarate hydratase-deficient renal cell carcinoma (FHRCC): outcome on first-line immune checkpoint inhibitor (ICI) combination: a multicenter retrospective study (FUMAHRE study).
Saved in:
| Title: | 2680eP Metastatic fumarate hydratase-deficient renal cell carcinoma (FHRCC): outcome on first-line immune checkpoint inhibitor (ICI) combination: a multicenter retrospective study (FUMAHRE study). |
|---|---|
| Authors: | Guida, A.1 (AUTHOR), Bimbatti, D.2 (AUTHOR), Di Marco, A.2 (AUTHOR), Calabrese, M.3 (AUTHOR), Beuselinck, B.4 (AUTHOR), Ciccarese, C.5 (AUTHOR), Quattrocchi, A.M.O.6 (AUTHOR), Messina, C.7 (AUTHOR), Conteduca, V.8 (AUTHOR), Stellato, M.9 (AUTHOR), Maiorano, B.A.10 (AUTHOR), Mammone, G.1 (AUTHOR), Imperi, M.11 (AUTHOR), Francesconi, S.12 (AUTHOR), Gili, A.13 (AUTHOR), Albiges, L.14 (AUTHOR), Bracarda, S.15 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1430-S1430. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.08.3291 |
